STI-571: an anticancer protein-tyrosine kinase inhibitor.
about
DNA and the chromosome - varied targets for chemotherapyThe natural chemopreventive agent sulforaphane inhibits STAT5 activityCombination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.Bcr is a negative regulator of the Wnt signalling pathwayThe synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.Protein functional surfaces: global shape matching and local spatial alignments of ligand binding sites.Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/TxkSomatic pharmacogenomics in cancer.Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release.Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.Different role of cAMP pathway on the human mast cells HMC-1(560) and HMC-1(560,816) activation.Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.Protein kinase PKC delta and c-Abl are required for mitochondrial apoptosis induction by genotoxic stress in the absence of p53, p73 and Fas receptor.Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.New carboxamide derivatives bearing benzenesulphonamide as a selective COX-II inhibitor: Design, synthesis and structure-activity relationship.Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin.A fluorescence lifetime-based assay for abelson kinase.
P2860
Q24792540-AB67CD9D-1748-453B-9A7C-B89100A47E27Q28539573-D83A735A-B13E-4C3F-856C-3852BCB71AF5Q33576089-530AEF59-2A15-44F0-9E12-11AD34FEBFE8Q34046157-B0F5DE91-2091-44B9-8955-452B285B5C7AQ34353920-F99019CC-EA5C-4E9A-B84D-6AA5A5E80C41Q34367152-FCF66336-5A23-44F1-BC79-62E704FF6CD1Q35111380-3117762D-7FFF-4E29-A523-0017D0FA01DAQ35782893-C1FA97B8-AD42-4281-8CD4-A50E0E968321Q35868560-6EB60A59-C62A-40B5-B3C3-D38786B9B8F2Q36769047-887A94EC-E907-49DE-8F16-1B62004EA666Q37061605-5A8582B6-BEF9-4585-A834-581951B1EA6DQ37171086-146B88C1-3250-4AD9-A12E-A73ED23FECA2Q37235024-C4C8AED7-FAD1-4A63-9460-F18B6B16214BQ37622705-1FB9524B-1F13-4FD5-AA6F-B4FEDBEB339DQ38744729-56F84EAC-1BE2-4BCB-B5C4-265E875CEA7CQ39048486-8445E9D4-79F6-40DA-A56A-714664714332Q39392579-EC09DF43-73B5-4F2D-AECA-AB7B115CE454Q39440567-80BD07A2-CC89-40A6-BEC5-1C5716A01F74Q40219908-BD95D160-1CA0-4EC5-BF53-1C99349F171DQ40288815-68DBAF45-0E3B-4156-B6B4-AF5EF2C9864EQ40468950-22AF3A90-5644-4BB7-8A56-7EEC9F2873B9Q41702568-7C41F022-6711-4131-9AEB-4F1F6142BF44Q42052611-87607267-6909-4D81-AD0D-EC5B872F1993Q52899932-1393587C-54DD-462F-8774-CCCD0C2411C4
P2860
STI-571: an anticancer protein-tyrosine kinase inhibitor.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
STI-571: an anticancer protein-tyrosine kinase inhibitor.
@ast
STI-571: an anticancer protein-tyrosine kinase inhibitor.
@en
type
label
STI-571: an anticancer protein-tyrosine kinase inhibitor.
@ast
STI-571: an anticancer protein-tyrosine kinase inhibitor.
@en
prefLabel
STI-571: an anticancer protein-tyrosine kinase inhibitor.
@ast
STI-571: an anticancer protein-tyrosine kinase inhibitor.
@en
P1476
STI-571: an anticancer protein-tyrosine kinase inhibitor.
@en
P304
P356
10.1016/J.BBRC.2003.08.055
P407
P577
2003-10-01T00:00:00Z